Nozin Awarded Best Infection Prevention Products Rating by Leapfrog Group and Newsweek

The ratings list highlights the Best Health Care products that help patients and the health care workforce avoid infection

Bethesda, Md. (May 15, 2020) – Global Life Technologies Corp. (GLT), the maker of Nozin® Nasal Sanitizer® antiseptic, is proud to share that the Nozin MRSA Colonization Risk Mitigation Program was recently named one of The Leapfrog Group’s Best Infection Prevention Products for 2020. The Leapfrog Group, an independent nonprofit that evaluates health care quality, worked with Newsweek to compile the list, evaluating products based on effectiveness, safety, successful real-world implementation, and the stability of the company.

This Nozin infection prevention program has been shown to reduce MRSA (methicillin resistant Staphylococcus aureus) infection risks in hospitals and surgery centers by up to 81 percent1. The Program utilizes Nozin® Nasal Sanitizer® antiseptic, an innovative product that benefits patients and healthcare workers by reducing the levels of dangerous pathogens in the nose. Nasal colonization is the top risk factor for MRSA healthcare-associated infection (HAI). Nozin® Nasal Sanitizer® is the #1 product used by hospitals to reduce the risk that MRSA nasal colonization represents for their patients. Nozin Nasal Sanitizer employs a patented Nozaseptin® formulation that delivers fast pathogen reduction and 12-hour persistence in a safe, pleasant application.

The Nozin MRSA Colonization Risk Mitigation Program allows hospitals to reduce isolation of patients, decrease use of related PPE (personal protection equipment) by up to 40%, lower infection risks and improve utilization of staff time. In addition to providing experienced advisors, the Nozin Program offers proprietary analytical tools that help hospitals pinpoint needs and design customized solutions. An experienced Implementation team is also available to help with facility in-service and compliance.

“It is an honor to be selected by The Leapfrog Group and Newsweek for their Best Infection Prevention Products list,” said John Willimann, CEO of Global Life Technologies Corp. “We feel this is also recognition for the hundreds of hospitals that have adopted Nozin Programs and are reporting excellent outcomes. These facilities are achieving reduced infection risk, improved patient care, better staff time utilization and lower costs with Nozin as part of their innovative infection prevention programs.”


About Nozin and Global Life Technologies Corp.

Nozin is the leading brand in nasal decolonization. Nozin programs from Global Life Technologies Corp.
are empowering healthcare professionals in hundreds of hospitals. Designed to improve care, lower
infection risk and reduce healthcare costs, these programs utilize Nozin® Nasal Sanitizer® antiseptic with
clinically supported infection prevention solutions for healthcare facilities, their patients and the
providers who care for them.

Note: Nozin® and Nasal Sanitizer® are registered trademarks of Global Life Technologies Corp. All other
company and product names may be trademarks of their respective owners.

To learn more, visit and connect with us on Facebook, Twitter, and LinkedIn.

SOURCE Nozin; Global Life Technologies Corp.

1 Mullen A et al. Am J Infect Control 2017; 45(5):554-556.

Newsweek, Leapfrog Best Infection Prevention Products announcement link.

Health Professionals:
Request a comprehensive analysis of your MRSA & MSSA colonization risk mitigation protocols today.

© 2004-2021 Global Life Technologies Corp. All rights reserved. Nozin® Nasal Sanitizer® antiseptic is an OTC topical antiseptic drug and no claim is made that it has an effect on any specific disease. | Patent Nos.